鲁 茜

个人简历

徐州医科大学临床药物治疗学专业博士生导师，临床药学学科负责人，江苏省“青蓝工程”优秀教学团队带头人，江苏省“青蓝工程”中青年学术带头人。现任中国微循环学会微循环药物研究专委会委员、中国药学会儿童药物专委会委员、江苏省药理学会理事、江苏省医学会临床药学分会委员、江苏省研究型医院学会精益化用药研究与转化专业委员会委员等。主要从事糖尿病并发症的发病机制及药物防治，以及基因多态性与临床合理用药等方面的研究。主持国家自然科学基金3项，江苏省自然科学基金1项，高校自然科学基金重大项目1项等。以第一作者或通讯作者发表SCI收录论文30余篇，授权专利5项。

承担科研课题

1.    国家自然科学基金“磷酸化PDHA1调控VCAM1促进糖尿病肾病肾间质纤维化”，起止年月2025.01~2028.12，课题号82473983，课题负责人鲁茜，48万

2.    国家自然科学基金“糖尿病肾病中GABP调控肾小球系膜细胞增殖的作用机制及新化合物AB38b的干预效应”，起止年月2021.01~2024.12，课题号82073906，课题负责人鲁茜，55万

3.    国家自然科学基金“Hippo通路在高糖诱导的肾小球系膜细胞增殖中的作用及机制”，起止年月2015.1~2017.12，课题号81400741，课题负责人鲁茜，23万

4.    江苏省自然科学基金面上项目“磷酸化PDHA1在糖尿病肾病肾间质纤维化中的作用及小分子化合物CHEMBL5079107的干预效应”，起止年月2024.9~2027.8，课题号BK20241958，课题负责人鲁茜，15万

5.    江苏省高校自然科学基金重大项目课题“Lnc-SLC35C1-83:4调控糖尿病肾病肾小球硬化的分子机制研究”，起止年月2019.9~2022.8，课题号19KJA460008，课题负责人鲁茜，30万

近五年代表性论文

1.    Yang T, Qiu Z, Shen J, He Y, Yin L, Chen L, Yuan J, Liu J, Wang T, Jiang Z, Ying C, Qian S, Song J, Yin X, Lu Q*. 17β-Estradiol, through activating the G protein-coupled estrogen receptor, exacerbates the complication of benign prostatic hyperplasia in type 2 diabetes mellitus patients by inducing prostate proliferation. J Pharm Anal. 2024 Sep;14(9):100962.

2.    Zhang W, Cheng Q, Yin L, Liu Y, Chen L, Jiang Z, Jiang X, Qian S, Li B, Wu M, Yin X, Wang T, Lu Q*, Yang T*. Jujuboside A through YY1/CYP2E1 signaling alleviated type 2 diabetes-associated fatty liver disease by ameliorating hepatic lipid accumulation, inflammation, and oxidative stress. Chem Biol Interact. 2024 Sep 1;400:111157.

3.    Yang T, Yuan J, Peng Y, Pang J, Qiu Z, Chen S, Huang Y, Jiang Z, Fan Y, Liu J, Wang T, Zhou X, Qian S, Song J, Xu Y, Lu Q*, Yin X*. Metformin: A promising clinical therapeutical approach for BPH treatment via inhibiting dysregulated steroid hormones-induced prostatic epithelial cells proliferation. J Pharm Anal. 2024 Jan;14(1):52-68.

4.    Du L, Chen Y, Shi J, Yu X, Zhou J, Wang X, Xu L, Liu J, Gao J, Gu X, Wang T, Yin Z, Li C, Yan M, Wang J, Yin X, Lu Q*. Inhibition of S100A8/A9 ameliorates renal interstitial fibrosis in diabetic nephropathy. Metabolism. 2023 Jul;144:155376.

5.    Yang T, Hu Y, Jiang W, Pang J, Zhou Y, Zhang H, Yin Z, Jiang Z, Qian S, Wei C, Yan M, Zhu X, Wang T, Lu Q*. YY1 was indispensable for the alleviation of quercetin on diabetic nephropathy-associated tubulointerstitial inflammation. Phytomedicine. 2023 Jan 11;111: 154659. 

6.    Yang T, Hu Y, Chen S, Li L, Cao X, Yuan J, Shu F, Jiang Z, Qian S, Zhu X, Wei C, Wei R, Yan M, Li C, Yin X*, Lu Q*. YY1 inactivated transcription co-regulator PGC-1α to promote mitochondrial dysfunction of early diabetic nephropathy-associated tubulointerstitial fibrosis. Cell Biol Toxicol. 2022 Apr 21.

7.    Liu Y, Li L, Ji B, Hao SL, Kuang XF, Cao XY, Yuan JY, Jiang ZZ, Qian ST, Wei CJ, Xu J, Yin XX, Lu Q*, Yang TT*. Jujuboside A ameliorated tubulointerstitial fibrosis of diabetic mice via down-regulating YY1/TGF-β1 signaling pathway. Chinese Journal of Natural Medicines, 2022, Sep;20(9):656-668.

8.    Liu Y, Li Y, Xu L, Shi J, Yu X, Wang X, Li X, Jiang H, Yang T, Yin X, Du L*, Lu Q*. Quercetin Attenuates Podocyte Apoptosis of Diabetic Nephropathy Through Targeting EGFR Signaling. Front Pharmacol. 2022 Jan 5; 12:792777.

9.    Gao T, Gao C, Liu Z, Wang Y, Jia X, Tian H, Lu Q*, Guo L*. Inhibition of Noncanonical Ca2+ Oscillation/Calcineurin/GSK-3β Pathway Contributes to Anti-Inflammatory Effect of Sigma-1 Receptor Activation. Neurochem Res. 2022 Feb;47(2):264-278.

10.Wang T, Song JF, Zhou XY, Li CL, Yin XX*, Lu Q*. PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus. BMC Med Genomics. 2021 Nov 12;14(1):267.

11.Qian X, Li Y, Hao M, Li CC, Li XZ, Wang L, Chen YB, Yang H, Du L, Yin XX, Lu Q*. YAP mediated interaction between Hippo pathway and PI3K/Akt Pathways in the mesangial cell proliferation of Diabetic Nephropathy. Acta Diabetol. 2021 Jan;58(1):47-62.

12.Yang TT, Yang H, Heng C, Wang HY, Chen SX, Hu YL, Jiang ZZ, Yu QN, Wang ZJ, Qian ST, Wang JY, Wang T, Du L, Lu Q*, Yin XX*. Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. Food Funct. 2020 Dec 1;11(12):10675-10689.

13.Wang T, Zhang F, Wang XT, Li XZ, Ling HW, Lv DM, Yin XX*, Lu Q*. Predictive factors associated with glycemic response to exenatide in Chinese patients with type 2 diabetes mellitus. Journal of Clinical Pharmacy and Therapeutics, 2020,10,45(5):1050-1057.

14.Yang TT, Heng C, Zhou Y, Hu YL, Chen SX, Wang HY, Yang H, Jiang ZZ, Qian ST, Wang YN, Wang JY, Zhu X, Du L, Yin XX, Lu Q*. Targeting mammalian serine/threonine-protein kinase 4 through yes-associated protein/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis. Metabolism. 2020,108:154258.

15.Yang TT, Zhou Y, Wang HY, Chen SX, Shen ML, Hu YL, Wang T, Liu JJ, Jiang ZZ, Wang ZJ, Zhu X, Qian ST, Yin XX, Lu Q∗. Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway. Exp Cell Res. 2020 Jun 16;112145.

16.Yang TT, Huang YH, Zhou Y, Chen SX, Wang HY, Hu YL, Liu JJ, Jiang ZZ, Lu Q*, Yin XX*. Simultaneous quantification of oestrogens and androgens in the serum of patients with benign prostatic hyperplasia by liquid chromatography-Tandem mass spectrometry. Andrologia. 2020 May 22; e13611.

17.Du L, Wang L, Wang B, Wang J, Hao M, Chen YB, Li XZ, Li Y, Jiang YF, Li CC, Yang H, Gu XK, Yin XX, Lu Q*. A novel compound AB38b attenuates oxidative stress and ECM protein accumulation in kidneys of diabetic mice through modulation of Keap1/Nrf2 signaling. Acta Pharmacol Sin. 2020 Mar;41(3):358-372.

18.Du L, Wang J, Chen Y, Li X, Wang L, Li Y, Jin X, Gu X, Hao M, Zhu X, Yin X, Lu Q*. Novel biphenyl diester derivative AB-38b inhibits NLRP3 inflammasome through Nrf2 activation in diabetic nephropathy. Cell Biol Toxicol. 2020 Jun;36(3):243-260.

19.Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, Du L, Mao S, Yin X, Lu Q*. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress and lipid metabolism in db/db mice. Phytother Res. 2019,33(12):3140-3152.

20.Lu Q, Chen YB, Yang H, Wang WW, Li CC, Wang L, Wang J, Du L, Yin XX*. Inactivation of TSC1 promotes epithelial-mesenchymal transition of renal tubular epithelial cells in mouse diabetic nephropathy. Acta Pharmacol Sin. 2019,40(12):1555-1567.

21.Du L, Li CC, Qian X, Chen YB, Wang L, Yang H, Li XZ, Li Y, Yin XX*, Lu Q*. Quercetin inhibited mesangial cell proliferation of early diabetic nephropathy through the Hippo pathway. Pharmacol Res. 2019; 146:104320.

22.Yang T, Shu F, Yang H, Heng C, Zhou Y, Chen Y, Qian X, Du L, Zhu X, Lu Q*, Yin X*. YY1: A novel therapeutic target for diabetic nephropathy orchestrated renal fibrosis. Metabolism. 2019; 96:33-45.

23.Lu Q, Wang WW, Zhang MZ, Ma ZX, Qiu XR, Shen ML, Yin XX*. ROS induces epithelial‑mesenchymal transition via the TGF‑β1/PI3K/Akt/mTOR pathway in diabetic nephropathy. Exp Ther Med. 2019; 17:835-846.